4/9/2013

Cash-strapped European governments have been balking at high prices for drugs to treat rare diseases, sometimes winning significant price concessions from manufacturers. Payers in the U.S. are likely to follow suit, says Mary Dunkle, a vice president at patient advocacy group National Organization for Rare Disorders. Thirteen European Union members are considering a plan to collaborate on cost-benefit analyses of orphan drugs, which might increase access across Europe, says Richard Bergstrom, director general of the European Federation of Pharmaceutical Industries and Associations.

Full Story:
Bloomberg

Related Summaries